<DOC>
	<DOCNO>NCT02528708</DOCNO>
	<brief_summary>In prospective , single-center , randomize , placebo-controlled , double-blind clinical trial , parturients primary PPH eligible treatment fibrinogen concentrate follow vaginal delivery cesarean section complicate estimate blood loss ( EBL ) &gt; 1000 mL ongoing bleed notwithstanding standard treatment measure ( volume replacement , uterine massage , uterotonic agent ) .</brief_summary>
	<brief_title>A Program Evaluate Riastap® FIBTEM® Early Control Treatment Postpartum Hemorrhage ( PERFECT PPH )</brief_title>
	<detailed_description>The propose trial target early detection treatment fibrinogen depletion PPH . A widespread belief benefit early fibrinogen substitution case PPH lead increase use indication . The PERFECT PPH aim provide evidence-based knowledge recommendation early use fibrinogen concentrate PPH .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Postpartum Hemorrhage</mesh_term>
	<criteria>Informed consent participant Age ≥18 year &lt; 50 year Primary PPH define bleed uterus and/or birth canal within 24 hour postpartum Vaginal delivery Cesarean delivery ( irrespective etiology PPH , accreta ) , EBL &gt; 1000 mL ongoing bleed notwithstanding standard treatment measure ( volume replacement , uterine massage , uterotonic agent ) FIBTEM® A10 &lt; 18 mm ( correspond MCF value &lt; 20 mm plasma fibrinogen level approximately &lt; 3 g/L ) Refusal give write informed consent Refusal receive blood transfusion Known inherit deficiency coagulation Personal history thrombosis Either prepregnancy antepartum antithrombotic treatment due increase risk thrombosis Administration Platelets , FFP cryotherapy prior study drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>fibrinogen concentrate</keyword>
	<keyword>coagulation</keyword>
</DOC>